CJM-112 is under clinical development by Novartis and currently in Phase II for Acne Vulgaris. According to GlobalData, Phase II drugs for Acne Vulgaris have a 40% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how CJM-112’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CJM-112 is under development for the treatment of neutrophilic asthma and acne vulgaris. It was under development for the treatment of hidradenitis suppurativa, relapsing-remitting multiple sclerosis. It is administered subcutaneously. The therapeutic candidate is an anti-interleukin-17 monoclonal antibody. It was also under development for chronic plaque-type psoriasis.
It was under development for the treatment of relapsed refractory multiple myeloma.
Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, hematologic diseases, solid tumors, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
For a complete picture of CJM-112’s drug-specific PTSR and LoA scores, buy the report here.